Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease
Background: Fecal and immunological biomarkers can be used to diagnose and manage patients with Crohn’s disease (CD). Anti -tumor necrosis factor (TNF) should be evaluated in addition to biomarkers to determine the response to therapy.Objectives: The current study aimed at following up fe...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Shiraz University of Medical Sciences
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1b051dfe7da24b779665674fcd79b43c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1b051dfe7da24b779665674fcd79b43c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1b051dfe7da24b779665674fcd79b43c2021-11-20T07:10:17ZDynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease2783-2430https://doaj.org/article/1b051dfe7da24b779665674fcd79b43c2018-03-01T00:00:00Zhttps://colorectalresearch.sums.ac.ir/article_47167_fe82d5e8d27380138a5ee05afed5d8a3.pdfhttps://doaj.org/toc/2783-2430Background: Fecal and immunological biomarkers can be used to diagnose and manage patients with Crohn’s disease (CD). Anti -tumor necrosis factor (TNF) should be evaluated in addition to biomarkers to determine the response to therapy.Objectives: The current study aimed at following up fecal calprotectin (FC), perinuclear anti - neutrophil cytoplasmic antibodies(pANCA), anti - Saccharomyces cerevisiae antibodies (ASCA), and anti - nuclear antibodies (ANA) in patients with CD on anti-TNFtherapy.Methods: A total of 57 patients with CD and the mean age of 40±15 years (ranged: 20 - 75) were monitored after initiation of anti- TNFa treatment. Stool samples were tested for FC (Alegria automated the enzyme - linked immunosorbent assay (ELISA) system),and serum samples for ANCA, ANA (indirect immunofluorescence - IIF), and ASCA (ELISA) in the beginning and after six months onimmunosuppressive therapy plus anti - TNFa agents.Results: Itwasobserved that all patients withCDhadsignificantly decreased FC levels after anti -TNFatherapy (963.97mg/kginitiallyvs. 268.42 mg/kg after treatment; P = 0.043). Moreover, in 75% of patients, FC levels dropped below the cutoff value of 50 mg/kg.Positive for ASCAIgA/IgG were 17/24 tested patients, butnodifferences were observed regarding the application of anti - TNFa therapy.However, the titers of pANCA decreased in four patients after anti - TNFa treatment. Conclusions: Initial and follow - up measurements of some immunological markers such as FC and pANCA could be of benefit forpatients with CD in anti - TNF therapy, whereas others such as ANA and ASCA were not useful to monitor the therapy.Tsvetelina Veselinova VelikovaZoya Angelova SpassovaLyuben Mitkov MilatchkovDobriana Georgieva PanovaEkaterina Ivanova Ivanova - TodorovaKalina Dinkova Tumangelova - YuzeirEkaterina Krasimirova KurtevaDobroslav Stanimirov KyurkchievSiragan Arshavir DeredjanRosen Kirilov NikolovIskra Petrova AltankovaLyudmila Mateva VladimirovaShiraz University of Medical Sciencesarticletnfa inhibitorsimmunological biomarkerstherapy monitoringMedicineRENIranian Journal of Colorectal Research, Vol 6, Iss 1 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
tnfa inhibitors immunological biomarkers therapy monitoring Medicine R |
| spellingShingle |
tnfa inhibitors immunological biomarkers therapy monitoring Medicine R Tsvetelina Veselinova Velikova Zoya Angelova Spassova Lyuben Mitkov Milatchkov Dobriana Georgieva Panova Ekaterina Ivanova Ivanova - Todorova Kalina Dinkova Tumangelova - Yuzeir Ekaterina Krasimirova Kurteva Dobroslav Stanimirov Kyurkchiev Siragan Arshavir Deredjan Rosen Kirilov Nikolov Iskra Petrova Altankova Lyudmila Mateva Vladimirova Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease |
| description |
Background: Fecal and immunological biomarkers can be used to diagnose and manage patients with Crohn’s disease (CD). Anti -tumor necrosis factor (TNF)
should be evaluated in addition to biomarkers to determine the response to therapy.Objectives: The current study aimed at following up fecal calprotectin (FC), perinuclear anti - neutrophil
cytoplasmic antibodies(pANCA), anti - Saccharomyces cerevisiae antibodies (ASCA), and anti - nuclear antibodies (ANA) in patients with CD on anti-TNFtherapy.Methods: A total of 57 patients
with CD and the mean age of 40±15 years (ranged: 20 - 75) were monitored after initiation of anti- TNFa treatment. Stool samples were tested for FC (Alegria automated the enzyme - linked
immunosorbent assay (ELISA) system),and serum samples for ANCA, ANA (indirect immunofluorescence - IIF), and ASCA (ELISA) in the beginning and after six months onimmunosuppressive
therapy plus anti - TNFa agents.Results: Itwasobserved that all patients withCDhadsignificantly decreased FC levels after anti -TNFatherapy (963.97mg/kginitiallyvs. 268.42 mg/kg
after treatment; P = 0.043). Moreover, in 75% of patients, FC levels dropped below the cutoff value of 50 mg/kg.Positive for ASCAIgA/IgG were 17/24 tested patients,
butnodifferences were observed regarding the application of anti - TNFa therapy.However, the titers of pANCA decreased in four patients after anti - TNFa treatment.
Conclusions: Initial and follow - up measurements of some immunological markers such as FC and pANCA could be of benefit forpatients with CD in anti - TNF therapy,
whereas others such as ANA and ASCA were not useful to monitor the therapy. |
| format |
article |
| author |
Tsvetelina Veselinova Velikova Zoya Angelova Spassova Lyuben Mitkov Milatchkov Dobriana Georgieva Panova Ekaterina Ivanova Ivanova - Todorova Kalina Dinkova Tumangelova - Yuzeir Ekaterina Krasimirova Kurteva Dobroslav Stanimirov Kyurkchiev Siragan Arshavir Deredjan Rosen Kirilov Nikolov Iskra Petrova Altankova Lyudmila Mateva Vladimirova |
| author_facet |
Tsvetelina Veselinova Velikova Zoya Angelova Spassova Lyuben Mitkov Milatchkov Dobriana Georgieva Panova Ekaterina Ivanova Ivanova - Todorova Kalina Dinkova Tumangelova - Yuzeir Ekaterina Krasimirova Kurteva Dobroslav Stanimirov Kyurkchiev Siragan Arshavir Deredjan Rosen Kirilov Nikolov Iskra Petrova Altankova Lyudmila Mateva Vladimirova |
| author_sort |
Tsvetelina Veselinova Velikova |
| title |
Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease |
| title_short |
Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease |
| title_full |
Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease |
| title_fullStr |
Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease |
| title_full_unstemmed |
Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease |
| title_sort |
dynamics of some routine immunological parameters during anti - tnf therapy in patients with crohn’s disease |
| publisher |
Shiraz University of Medical Sciences |
| publishDate |
2018 |
| url |
https://doaj.org/article/1b051dfe7da24b779665674fcd79b43c |
| work_keys_str_mv |
AT tsvetelinaveselinovavelikova dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease AT zoyaangelovaspassova dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease AT lyubenmitkovmilatchkov dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease AT dobrianageorgievapanova dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease AT ekaterinaivanovaivanovatodorova dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease AT kalinadinkovatumangelovayuzeir dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease AT ekaterinakrasimirovakurteva dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease AT dobroslavstanimirovkyurkchiev dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease AT siraganarshavirderedjan dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease AT rosenkirilovnikolov dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease AT iskrapetrovaaltankova dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease AT lyudmilamatevavladimirova dynamicsofsomeroutineimmunologicalparametersduringantitnftherapyinpatientswithcrohnsdisease |
| _version_ |
1718419467949572096 |